|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Reference Compounds
|
BML-190(BML 190)
| Catalogue No. : |
C16367 |
| Product Name: |
BML-190(BML 190) |
| Synonym: |
BML-190;BML 190;BML190;Indomethacin morpholinylamide;IMMA;LM-4131 |
| Chemical Name: |
2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-(4-morpholinyl)ethanone;1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-1H-indole; 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-[(morpholinocarbonyl)methyl]-indole |
| CAS No. : |
2854-32-2 |
| Structure : |
|
| Molecular Formula: |
C23H23ClN2O4 |
| Molecular Weight: |
426.89 |
| Purity: |
>98% |
| Usage: |
BML-190 is an indomethacin morpholinylamide which functions as a selective inverse agonist of the human cannabinoid CB2 receptor. It is known that BML-190 binds to both CB1 and CB2 receptors. Studies involving HEK-293 cells indicate that BML-190 increases the accumulation of cAMP, via forskolin-stimulated mechanism. Alternate studies suggest that BML-190 reduces the toxicity of culture supernatants to SH-SY5Y human neutroblastoma cells. Various research suggests that BML-190 is an essential tool in studying the proliferation of neuroblastoma. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
